ProQR Therapeutics NV
PRQR2.070USD
-0.010-0.48%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
222.96MCap. mercado
PérdidaP/E TTM
Más Datos de ProQR Therapeutics NV Compañía
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Información de la empresa
Símbolo de cotizaciónPRQR
Nombre de la empresaProQR Therapeutics NV
Fecha de salida a bolsaSep 18, 2014
Director ejecutivoMr. Daniel Anton de Boer
Número de empleados166
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 18
DirecciónZernikedreef 9
CiudadLEIDEN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísNetherlands
Código postal2333 CK
Teléfono31881667000
Sitio Webhttps://www.proqr.com/
Símbolo de cotizaciónPRQR
Fecha de salida a bolsaSep 18, 2014
Director ejecutivoMr. Daniel Anton de Boer
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Eli Lilly and Company
16.06%
Van Herk Investments
10.93%
Adage Capital Management, L.P.
7.70%
Privium Fund Management BV
4.75%
Affinity Asset Advisors LLC
3.12%
Other
57.44%
Accionistas
Accionistas
Proporción
Eli Lilly and Company
16.06%
Van Herk Investments
10.93%
Adage Capital Management, L.P.
7.70%
Privium Fund Management BV
4.75%
Affinity Asset Advisors LLC
3.12%
Other
57.44%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
21.84%
Corporation
16.06%
Investment Advisor
11.42%
Family Office
10.93%
Investment Advisor/Hedge Fund
4.91%
Individual Investor
2.00%
Research Firm
1.72%
Bank and Trust
0.04%
Venture Capital
0.02%
Other
31.06%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
122
61.04M
58.02%
-5.87M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
2023Q1
180
47.05M
58.19%
-9.38M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Eli Lilly and Company
16.90M
16.06%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
11.50M
10.93%
+40.00K
+0.35%
May 23, 2025
Adage Capital Management, L.P.
8.10M
7.7%
-1.50M
-15.62%
Mar 31, 2025
Privium Fund Management BV
4.99M
4.74%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
3.28M
3.12%
+459.51K
+16.27%
Mar 31, 2025
Millennium Management LLC
2.07M
1.97%
-756.63K
-26.76%
Mar 31, 2025
Sio Capital Management, LLC
2.05M
1.95%
--
--
Mar 31, 2025
abrdn Inc.
1.85M
1.76%
+1.85M
--
Mar 31, 2025
UBS Financial Services, Inc.
1.78M
1.69%
-511.49K
-22.30%
Mar 31, 2025
Kynam Capital Management LP
1.75M
1.66%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
0%
Avantis International Small Cap Value ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Avantis International Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
